1.0
2. Sept. 2024
Aktueller Mitarbeiter, mehr als 5 Jahre
Barcelona
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Interactions with FDA, EMA and local agencies at the Regulatory Department
Kontras
In the Clinical Development Dpt, employees without elemental medical and scientific knowledge, lack of GCP rules during the trial execution, many problems with many "interpretations" of study protocol and data leading to very poor results